Skip to content

XENETIC BIOSCIENCES, INC.: 10-Q filed 2023-08-10

What XENETIC BIOSCIENCES, INC. reported in its quarterly report filed 2023-08-10 (fiscal Q2 2023): 32 published measures, 98 facts as tagged in accession 0001683168-23-005513.

This filing

Form
10-Q (quarterly report)
Filed
2023-08-10
Fiscal period
fiscal Q2 2023
Accession
0001683168-23-005513 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All XENETIC BIOSCIENCES, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2023-06-3012,749,173USD
At 2022-12-3114,720,290USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2023-06-30871,315USD
At 2022-12-311,073,156USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2023-06-3011,877,858USD
At 2023-03-3112,859,432USD
At 2022-12-3113,647,134USD
At 2022-06-3015,188,921USD
At 2022-03-3116,920,241USD
At 2021-12-3118,394,257USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-1,050,963USD91
2023-01-01 to 2023-06-30-1,907,517USD181
2022-04-01 to 2022-06-30-2,672,190USD91
2022-01-01 to 2022-06-30-4,265,801USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2023-01-01 to 2023-06-30-2,371,558USD181
2022-01-01 to 2022-06-30-2,816,590USD181

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2023-04-01 to 2023-06-30651,005USD91
2023-01-01 to 2023-06-301,256,849USD181
2022-04-01 to 2022-06-30416,710USD91
2022-01-01 to 2022-06-30805,703USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2023-01-01 to 2023-06-300USD181
2022-01-01 to 2022-06-30-500,000USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2023-06-30-191,007,135USD
At 2022-12-31-189,099,618USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2023-04-01 to 2023-06-301,524,717shares91
2023-01-01 to 2023-06-301,520,710shares181
2022-04-01 to 2022-06-301,406,657shares91
2022-01-01 to 2022-06-301,375,505shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2023-04-01 to 2023-06-301,524,717shares91
2023-01-01 to 2023-06-301,520,710shares181
2022-04-01 to 2022-06-301,406,657shares91
2022-01-01 to 2022-06-301,375,505shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-0.69USD/shares91
2023-01-01 to 2023-06-30-1.25USD/shares181
2022-04-01 to 2022-06-30-1.9USD/shares91
2022-01-01 to 2022-06-30-3.1USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-0.69USD/shares91
2023-01-01 to 2023-06-30-1.25USD/shares181
2022-04-01 to 2022-06-30-1.9USD/shares91
2022-01-01 to 2022-06-30-3.1USD/shares181

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2023-04-01 to 2023-06-300USD91
2023-01-01 to 2023-06-300USD181
2022-04-01 to 2022-06-300USD91
2022-01-01 to 2022-06-300USD181

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2023-04-01 to 2023-06-3069,389USD91
2023-01-01 to 2023-06-30138,241USD181
2022-04-01 to 2022-06-30135,870USD91
2022-01-01 to 2022-06-30255,465USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-1,198,188USD91
2023-01-01 to 2023-06-30-2,113,363USD181
2022-04-01 to 2022-06-30-2,687,079USD91
2022-01-01 to 2022-06-30-4,306,794USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2023-06-3012,044,742USD
At 2022-12-3113,653,359USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2023-06-30871,315USD
At 2022-12-311,073,156USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2023-06-30221,281USD
At 2022-12-31287,360USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2023-04-01 to 2023-06-301,849,193USD91
2023-01-01 to 2023-06-303,370,212USD181
2022-04-01 to 2022-06-303,103,789USD91
2022-01-01 to 2022-06-305,112,497USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2023-04-01 to 2023-06-30903,243USD91
2023-01-01 to 2023-06-301,498,519USD181
2022-04-01 to 2022-06-302,077,499USD91
2022-01-01 to 2022-06-303,178,898USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2023-06-301,532,600shares
At 2022-12-311,516,659shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2023-06-3010,725,707USD
At 2022-12-3113,097,265USD
At 2022-06-3014,927,440USD
At 2021-12-3118,244,030USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2023-06-30207,908,129USD
At 2022-12-31207,769,904USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2023-06-30253,734USD
At 2022-12-31253,734USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2023-06-300USD
At 2022-06-309,611USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2023-06-30704,431USD
At 2022-12-311,066,931USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2023-06-301,319,035USD
At 2022-12-31556,094USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2023-04-01 to 2023-06-30945,950USD91
2023-01-01 to 2023-06-301,871,693USD181
2022-04-01 to 2022-06-301,026,290USD91
2022-01-01 to 2022-06-301,933,599USD181

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2023-04-01 to 2023-06-3021,122USD91
2023-01-01 to 2023-06-3025,642USD181
2022-04-01 to 2022-06-30-1,076USD91
2022-01-01 to 2022-06-30-877USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2023-04-01 to 2023-06-30147,225USD91
2023-01-01 to 2023-06-30205,846USD181
2022-04-01 to 2022-06-3014,889USD91
2022-01-01 to 2022-06-3040,993USD181

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2023-01-01 to 2023-06-300USD181
2022-01-01 to 2022-06-300USD181

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

PeriodValueUnitDays
2023-01-01 to 2023-06-300USD181
2022-01-01 to 2022-06-3019,087USD181

Inspect the source

Entity
XENETIC BIOSCIENCES, INC. / CIK 0001534525
Captured
2026-09-20T09:16:43.632Z
SEC response SHA-256
0d9d849e14a36c3c398086c2983f13053152bb5ab9dbb765c6ab6226c86b34ff

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001534525.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))